RxSight, Inc. (RXST)
NASDAQ: RXST · Real-Time Price · USD
5.36
+0.23 (4.48%)
At close: Jun 26, 2026, 4:00 PM EDT
5.37
+0.01 (0.19%)
After-hours: Jun 26, 2026, 5:45 PM EDT

Company Description

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States.

It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.

The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery.

RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017.

The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.

RxSight, Inc.
RxSight logo
Country United States
Founded 1997
IPO Date Jul 30, 2021
Industry Medical Devices
Sector Healthcare
Employees 461
CEO Ronald Kurtz

Contact Details

Address:
100 Columbia
Aliso Viejo, California 92656
United States
Phone 949 521 7830
Website rxsight.com

Stock Details

Ticker Symbol RXST
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001111485
CUSIP Number 78349D107
ISIN Number US78349D1072
Employer ID 94-3268801
SIC Code 3851

Key Executives

Name Position
Dr. Ronald M. Kurtz M.D. President, Chief Executive Officer and Director
Dr. Ilya Goldshleger Ph.D. Chief Operating Officer
Eric J. Weinberg Chief Business Development Officer

Latest SEC Filings

Date Type Title
Jun 16, 2026 8-K Current Report
May 29, 2026 SD Form - SD
May 13, 2026 SCHEDULE 13G/A Filing
May 6, 2026 10-Q Quarterly Report
May 6, 2026 8-K Current Report
Apr 28, 2026 ARS Filing
Apr 28, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 28, 2026 DEF 14A Other definitive proxy statements
Mar 27, 2026 SCHEDULE 13G/A Filing
Mar 19, 2026 8-K/A [Amend] Current report